What Is SS-31 (Elamret)?
SS-31 (Elamret) is a mitochondria-targeting peptide that stabilizes the inner mitochondrial membrane to protect energy production. It's FDA-approved for a rare mitochondrial disease.
SS-31 targets a problem most people don't even know they have: damaged mitochondria. If you're dealing with unexplained fatigue, brain fog, slow recovery, or a general sense that your body just isn't producing energy the way it used to, mitochondrial dysfunction might be the reason. And SS-31 is one of the few peptides specifically designed to address it.
SS-31 — also known as Elamret or elamipretide — is actually FDA-approved for a specific rare mitochondrial disease. But the research suggests its benefits extend well beyond that one condition.
What Mitochondria Do (And Why They Matter)
Before understanding SS-31, you need to understand why mitochondria matter.
Mitochondria are the energy factories inside nearly every cell in your body. They produce ATP (adenosine triphosphate) — the molecule your cells use as fuel for literally everything: muscle contraction, brain function, immune response, tissue repair, hormone production, digestion.
You have trillions of mitochondria. Organs with high energy demands — your brain, heart, muscles, liver — have the most. When mitochondria work well, you have energy, mental clarity, and your body recovers efficiently. When they don't, everything suffers.
What Damages Mitochondria
- Oxidative stress — free radicals produced during normal energy production damage mitochondrial structures over time
- Chronic inflammation — inflammatory signals directly impair mitochondrial function
- Aging — mitochondrial efficiency declines steadily with age
- Poor sleep — sleep is when mitochondrial repair happens; chronic sleep deprivation compounds damage
- Metabolic stress — poor diet, insulin resistance, and chronic overwork burden mitochondria beyond their capacity
The result of mitochondrial damage: fatigue that sleep doesn't fix, brain fog, slow wound healing, reduced exercise capacity, and accelerated aging. Sound familiar?
How SS-31 Works
SS-31's mechanism is specific and well-understood:
Cardiolipin Binding
The inner mitochondrial membrane has a molecule called cardiolipin that's essential for energy production. Cardiolipin helps organize the electron transport chain — the assembly line inside mitochondria that produces ATP.
When cardiolipin gets damaged by oxidative stress or inflammation, the assembly line falls apart. Energy production drops. Damaged mitochondria also produce more free radicals, which damage more cardiolipin, creating a vicious cycle.
SS-31 binds directly to cardiolipin and stabilizes it. It protects the structural integrity of the inner mitochondrial membrane, keeping the energy-producing machinery intact and functional.
Reducing Oxidative Stress
By stabilizing the mitochondrial membrane, SS-31 reduces the leakage of electrons that produces free radicals. Less free radical production means less oxidative damage, which means less cardiolipin damage, which breaks the vicious cycle.
Improving ATP Production
With stabilized cardiolipin and reduced oxidative stress, the electron transport chain functions more efficiently. More efficient energy production means more ATP available for every cell in your body.
Mitochondrial Membrane Potential
SS-31 helps maintain proper membrane potential — the electrical charge across the inner mitochondrial membrane that drives ATP synthesis. When membrane potential drops, energy production drops with it. SS-31 helps keep it stable.
What the Research Shows
Barth Syndrome (Human Data — FDA Approved)
SS-31 (as elamipretide) is FDA-approved for Barth syndrome, a rare genetic mitochondrial disease that causes heart failure, muscle weakness, and fatigue. In clinical trials, patients showed improved exercise capacity, cardiac function, and quality of life.
This is significant because it demonstrates the peptide works on mitochondria in living humans, not just test tubes or animals.
Heart Failure (Human Clinical Trials)
SS-31 has been studied in human clinical trials for heart failure with preserved ejection fraction (HFpEF). The heart is one of the most mitochondria-dense organs in the body. Early trial results showed improvements in cardiac function, though results across trials have been mixed.
Age-Related Mitochondrial Decline (Animal Data)
Animal studies have shown that SS-31 can reverse age-related mitochondrial dysfunction. In aged mice, SS-31 treatment improved mitochondrial function, reduced oxidative stress, and restored energy production toward levels seen in younger animals. It also improved exercise capacity in aged mice.
Kidney Protection (Animal Data)
Animal studies show SS-31 can protect kidney tissue from ischemia-reperfusion injury — the damage that occurs when blood flow is temporarily cut off and then restored. This is relevant for surgery, transplant, and acute kidney injury.
Skeletal Muscle Function (Animal and Human Data)
Research has shown SS-31 improves skeletal muscle mitochondrial function in both animals and humans. In elderly human subjects, SS-31 improved mitochondrial ATP production in muscle tissue.
Neurodegenerative Research (Animal Data)
Early animal studies suggest SS-31 may have neuroprotective effects by reducing mitochondrial dysfunction in brain cells. This is being explored in the context of Alzheimer's, Parkinson's, and age-related cognitive decline. Preliminary, but logical given the brain's enormous mitochondrial dependence.
How People Use SS-31
Subcutaneous Injection
The primary route. SS-31 is typically injected subcutaneously once daily. In clinical trials for Barth syndrome, the approved dose was 40 mg/day. Community protocols for general mitochondrial support typically use much lower doses — 5-20 mg per day.
Duration
Clinical trials used treatment periods of weeks to months. Community use varies — some people use it in cycles of 4-8 weeks, others use lower doses on an ongoing basis.
Who Uses It
SS-31 attracts a specific audience:
- People with chronic fatigue that doesn't respond to conventional approaches
- Athletes looking to optimize recovery and energy production
- Older adults dealing with age-related energy decline
- People with known mitochondrial dysfunction
- Biohackers focused on longevity and cellular health
Safety
SS-31 has human safety data from clinical trials:
- FDA-approved for Barth syndrome with an established safety profile
- Clinical trial side effects were generally mild — injection site reactions, headache, nausea
- Serious adverse events were rare in trial populations
- The peptide specifically targets mitochondrial membranes, so its action is relatively focused
SS-31 is one of the few peptides in the biohacking space with actual human clinical trial safety data, which puts it in a different category than many research-chemical-only peptides.
However, the FDA approval is for a specific rare disease. Using it off-label for general energy or anti-aging purposes is not FDA-sanctioned, and long-term safety data for that use case doesn't exist.
The Bottom Line
SS-31 goes after the root of cellular energy production. By stabilizing cardiolipin in the inner mitochondrial membrane, it protects the machinery that produces ATP — the fuel for everything your body does. It has FDA approval for a mitochondrial disease, human clinical trial data for heart failure, and compelling animal data for age-related mitochondrial decline.
If your issue is energy — real, cellular-level energy, not caffeine-and-willpower energy — SS-31 targets the actual mechanism. It's one of the more scientifically grounded peptides in the space, with a clearer evidence base than most.